2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations
3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 1997-04, Vol.323 (2), p.173-180 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 180 |
---|---|
container_issue | 2 |
container_start_page | 173 |
container_title | European journal of pharmacology |
container_volume | 323 |
creator | Miller, R.Timothy Lau, Serrine S Monks, Terrence J |
description | 3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the
o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion-
S-yl)-α-methyldopamine (4×720 nmol) and 5-(
N-acetylcystein-
S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. ©
1997 Elsevier Science B.V. All rights reserved. |
doi_str_mv | 10.1016/S0014-2999(97)00044-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16453266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299997000447</els_id><sourcerecordid>16453266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhQtRxnb0EQZqIdINHU3lp6qyEhl0FAZcjK5Dfm7oSFVSJtWD_R6-yLyCD-AzmZ4ueuvqBs537g3nVNVVg982uGnf3WHcMESEEGvRbTDGjKHuSbVq-k4g3DXkabU6I8-rFzn_KBAXhF9UF6IhfU_bVfWbbDmqtc9ofTPsZzXvfAyovkOHYYP-PqAR5t1hsHFSow-wrVU9HSl_D3WRlI6Dn6GOrl7_edggumWLAwJYH38d1DjtCncyWzAJVIZc66R8qDOkOMdQXiYGA2FOZXMM-WX1zKkhw6tlXlbfP338dv0Z3X69-XL94RYZRvCMjHOgnNbK8p45TLUApontubPciV50illFCQXBemtEqzl1um91Zyzl0BN6Wb057Z1S_LmHPMvRZwPDoALEfZZNyzglbVtAfgJNijkncHJKflTpIBssj23IxzbkMWopOvnYhuyK72o5sNcj2LNrib_orxddZaMGl1QwPp8x0tJOtLxg708YlDDuPSSZjYeSmPUJzCxt9P_5yD_cAKqE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16453266</pqid></control><display><type>article</type><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</creator><creatorcontrib>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</creatorcontrib><description>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the
o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion-
S-yl)-α-methyldopamine (4×720 nmol) and 5-(
N-acetylcystein-
S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. ©
1997 Elsevier Science B.V. All rights reserved.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(97)00044-7</identifier><identifier>PMID: 9128836</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>3,4-Methylenedioxyamphetamine - toxicity ; 5-HT (5-hydroxytryptamine, serotonin) ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Cerebral Cortex - drug effects ; Cerebral Cortex - metabolism ; Chemical and industrial products toxicology. Toxic occupational diseases ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Deoxyepinephrine - analogs & derivatives ; Deoxyepinephrine - toxicity ; Depression, Chemical ; Glutathione ; Glutathione - analogs & derivatives ; Glutathione - toxicity ; Hippocampus - drug effects ; Hippocampus - metabolism ; Male ; MDA (3,4-Methylenedioxyamphetamine) ; MDMA (3,4-Methylenedioxymethamphetamine) ; Medical sciences ; Neurotoxicity ; Rats ; Rats, Sprague-Dawley ; Serotonin - metabolism ; Serotonin Agents - toxicity ; Toxicology ; Various organic compounds ; α-Methyldopamine</subject><ispartof>European journal of pharmacology, 1997-04, Vol.323 (2), p.173-180</ispartof><rights>1997 Elsevier Science B.V.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</citedby><cites>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(97)00044-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2637965$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9128836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, R.Timothy</creatorcontrib><creatorcontrib>Lau, Serrine S</creatorcontrib><creatorcontrib>Monks, Terrence J</creatorcontrib><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the
o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion-
S-yl)-α-methyldopamine (4×720 nmol) and 5-(
N-acetylcystein-
S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. ©
1997 Elsevier Science B.V. All rights reserved.</description><subject>3,4-Methylenedioxyamphetamine - toxicity</subject><subject>5-HT (5-hydroxytryptamine, serotonin)</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - metabolism</subject><subject>Chemical and industrial products toxicology. Toxic occupational diseases</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Deoxyepinephrine - analogs & derivatives</subject><subject>Deoxyepinephrine - toxicity</subject><subject>Depression, Chemical</subject><subject>Glutathione</subject><subject>Glutathione - analogs & derivatives</subject><subject>Glutathione - toxicity</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Male</subject><subject>MDA (3,4-Methylenedioxyamphetamine)</subject><subject>MDMA (3,4-Methylenedioxymethamphetamine)</subject><subject>Medical sciences</subject><subject>Neurotoxicity</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Agents - toxicity</subject><subject>Toxicology</subject><subject>Various organic compounds</subject><subject>α-Methyldopamine</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2KFDEUhQtRxnb0EQZqIdINHU3lp6qyEhl0FAZcjK5Dfm7oSFVSJtWD_R6-yLyCD-AzmZ4ueuvqBs537g3nVNVVg982uGnf3WHcMESEEGvRbTDGjKHuSbVq-k4g3DXkabU6I8-rFzn_KBAXhF9UF6IhfU_bVfWbbDmqtc9ofTPsZzXvfAyovkOHYYP-PqAR5t1hsHFSow-wrVU9HSl_D3WRlI6Dn6GOrl7_edggumWLAwJYH38d1DjtCncyWzAJVIZc66R8qDOkOMdQXiYGA2FOZXMM-WX1zKkhw6tlXlbfP338dv0Z3X69-XL94RYZRvCMjHOgnNbK8p45TLUApontubPciV50illFCQXBemtEqzl1um91Zyzl0BN6Wb057Z1S_LmHPMvRZwPDoALEfZZNyzglbVtAfgJNijkncHJKflTpIBssj23IxzbkMWopOvnYhuyK72o5sNcj2LNrib_orxddZaMGl1QwPp8x0tJOtLxg708YlDDuPSSZjYeSmPUJzCxt9P_5yD_cAKqE</recordid><startdate>19970404</startdate><enddate>19970404</enddate><creator>Miller, R.Timothy</creator><creator>Lau, Serrine S</creator><creator>Monks, Terrence J</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>19970404</creationdate><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><author>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>3,4-Methylenedioxyamphetamine - toxicity</topic><topic>5-HT (5-hydroxytryptamine, serotonin)</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - metabolism</topic><topic>Chemical and industrial products toxicology. Toxic occupational diseases</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Deoxyepinephrine - analogs & derivatives</topic><topic>Deoxyepinephrine - toxicity</topic><topic>Depression, Chemical</topic><topic>Glutathione</topic><topic>Glutathione - analogs & derivatives</topic><topic>Glutathione - toxicity</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Male</topic><topic>MDA (3,4-Methylenedioxyamphetamine)</topic><topic>MDMA (3,4-Methylenedioxymethamphetamine)</topic><topic>Medical sciences</topic><topic>Neurotoxicity</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Agents - toxicity</topic><topic>Toxicology</topic><topic>Various organic compounds</topic><topic>α-Methyldopamine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, R.Timothy</creatorcontrib><creatorcontrib>Lau, Serrine S</creatorcontrib><creatorcontrib>Monks, Terrence J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, R.Timothy</au><au>Lau, Serrine S</au><au>Monks, Terrence J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1997-04-04</date><risdate>1997</risdate><volume>323</volume><issue>2</issue><spage>173</spage><epage>180</epage><pages>173-180</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the
o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion-
S-yl)-α-methyldopamine (4×720 nmol) and 5-(
N-acetylcystein-
S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5-
bis-(glutathion-
S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. ©
1997 Elsevier Science B.V. All rights reserved.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>9128836</pmid><doi>10.1016/S0014-2999(97)00044-7</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 1997-04, Vol.323 (2), p.173-180 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_16453266 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
subjects | 3,4-Methylenedioxyamphetamine - toxicity 5-HT (5-hydroxytryptamine, serotonin) Animals Behavior, Animal - drug effects Biological and medical sciences Brain - drug effects Brain - metabolism Cerebral Cortex - drug effects Cerebral Cortex - metabolism Chemical and industrial products toxicology. Toxic occupational diseases Corpus Striatum - drug effects Corpus Striatum - metabolism Deoxyepinephrine - analogs & derivatives Deoxyepinephrine - toxicity Depression, Chemical Glutathione Glutathione - analogs & derivatives Glutathione - toxicity Hippocampus - drug effects Hippocampus - metabolism Male MDA (3,4-Methylenedioxyamphetamine) MDMA (3,4-Methylenedioxymethamphetamine) Medical sciences Neurotoxicity Rats Rats, Sprague-Dawley Serotonin - metabolism Serotonin Agents - toxicity Toxicology Various organic compounds α-Methyldopamine |
title | 2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A54%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2,5-%20bis-(Glutathion-%20S-yl)-%CE%B1-methyldopamine,%20a%20putative%20metabolite%20of%20(%C2%B1)-3,4-methylenedioxyamphetamine,%20decreases%20brain%20serotonin%20concentrations&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Miller,%20R.Timothy&rft.date=1997-04-04&rft.volume=323&rft.issue=2&rft.spage=173&rft.epage=180&rft.pages=173-180&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(97)00044-7&rft_dat=%3Cproquest_cross%3E16453266%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16453266&rft_id=info:pmid/9128836&rft_els_id=S0014299997000447&rfr_iscdi=true |